Best practice in the treatment of nonmuscle invasive bladder cancer

Therapeutic Advances in Urology

Volumn 4, Issue 1, 2012, Pages 13-32

  Anastasiadis, Anastasios ^a   de Reijke, Theo M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

carcinoma in situ; chemotherapy; immunotherapy; noninvasive bladder tumour; transurethral resection

Indexed keywords

ANTINEOPLASTIC AGENT; APAZIQUONE; BCG VACCINE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; GLUCOCORTICOID; INTERFERON; ISONIAZID; MITOMYCIN C; OFLOXACIN; OXEDRINE TARTRATE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SYNERGO; UNCLASSIFIED DRUG;

BLADDER BIOPSY; BLADDER CANCER; BLADDER PERFORATION; BLEEDING; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CYSTECTOMY; CYSTITIS; CYSTOSCOPY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEVER; FLUORESENCE CYSTOSCOPY; FOLLOW UP; HEMATURIA; HEPATITIS; HUMAN; NONMUSCLE INVASIVE BLADDER CANCER; OPTICAL COHERENCE TOMOGRAPHY; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TRANSURETHRAL RESECTION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

EID: 84856065938     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287211431976     Document Type: Article

References (138)

1. Althausen A.F. Prout G.R. Jr D” Daly J.J. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol. 1976 Nov; 116(5): 575–580.
2. Augustine A. Hebert J.R. Kabat G.C. Wynder EL. Bladder cancer in relation to cigarette smoking. Cancer Res. 1988 Aug 1; 48(15): 4405–4408.
3. Aveyard P. Adab P. Cheng K.K. Wallace D.M. Hey K. Murphy M.F. Does smoking status influence the prognosis of bladder cancer? A systematic review. BJU Int. 2002 Aug; 90(3): 228–39. Review.
4. Barlow L. McKiernan J. Sawczuk I. Benson M. (2009) A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy. BJU Int 104: 1098–1102.
5. Bjerregaard B.K. Raaschou-Nielsen O. Sørensen M. Frederiksen K. Christensen J. Tjønneland A. Tobacco smoke and bladder cancer–in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2006 Nov 15; 119(10): 2412–6.
6. Böhle A. Leyh H. Frei C. Kühn M. Tschada R. Pottek T. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol. 2009 Sep; 56(3): 495–503. Epub 2009 Jun 21.
7. Borhan A. Reeder J.E. O–Connell M.J. Wright K.O. Wheeless L.L. di Sant–Agnese P.A. Grade progression and regression in recurrent urothelial cancer. J Urol. 2003 Jun; 169(6): 2106–2109.
8. Brausi M. Collette L. Kurth K. van der Meijden A.P. Oosterlinck W. Witjes J.A. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002 May; 41(5): 523–31.
9. Burger M. van der, Aa M.N. van Oers J.M. Brinkmann A. van der Kwast T.H. Steyerberg E.C. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol. 2008 Oct; 54(4): 835–43. Epub 2007 Dec 26.
10. Catalona W.J. Hudson M.A. Gillen D.P. Andriole G.L. Ratliff T.L. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol. 1987 Feb; 137(2): 220–224.
11. Cauberg E.C. de Bruin D.M. Faber D.J. de Reijke T.M. Visser M. de la Rosette J.J. van Leeuwen T.G. (2010) Quantitative measurement of attenuation coefficients of bladder biopsies using optical coherence tomography for grading urothelial carcinoma of the bladder. J Biomed Opt 15: 066013.
12. Cauberg E.C. Mamoulakis C. de la Rosette J.J. de Reijke T.M. (2011) Narrow band imaging-assisted transurethral resection for non-muscle invasive bladder cancer significantly reduces residual tumour rate. World J Urol 29: 503–509.
13. Chade D.C. Shariat S.F. Godoy G. Savage C.J. Cronin A.M. Bochner B.H. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol. 2010 Jul; 184(1): 74–80.
14. Cho K.S. Seo H.K. Joung J.Y. Park W.S. Ro J.Y. Han K.S. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol. 2009 Dec; 182(6): 2625–30. Epub 2009 Oct 17.
15. Collado A. Chéchile G.E. Salvador J. Vicente J. Early complications of endoscopic treatment for superficial bladder tumors. J Urol. 2000 Nov; 164(5): 1529–1532.
16. Colombel M. Saint F. Chopin D. Malavaud B. Nicolas L. Rischmann P. (2006) The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 176: 935–939.
17. Colombo R. Salonia A. Leib Z. Pavone-Macaluso M. Engelstein D. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011 Mar; 107(6): 912–918. doi: 10.1111/j.1464-410X.2010.09654.x10.1111/j.1464-410X.2010.09654.x. Epub 2010 Oct 4.
18. Cookson M.S. Sarosdy M.F. (1992) Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guérin therapy. J Urol 148: 797–801.
19. Crow P. Uff J.S. Farmer J.A. Wright M.P. Stone N. (2004) The use of Raman spectroscopy to identify and characterize transitional cell carcinoma in vitro. BJU Int 93: 1232–1236.
20. de Boer E.C. Rooyakkers S.J. Schamhart D.H. de Reijke T.M. Kurth K.H. BCG dose reduction by decreasing the instillation frequency: effects on local Th1/Th2 cytokine responses in a mouse model. Eur Urol. 2005 Aug; 48(2): 333–338.
21. de Jong B.W. Bakker Schut T.C. Wolffenbuttel K.P. Nijman J.M. Kok D.J. Puppels G.J. (2002) Identification of bladder wall layers by Raman spectroscopy. J Urol 168: 1771–1778.
22. de Reijke T.M. de Boer E.C. Kurth K.H. Schamhart D.H. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol. 1996 Feb; 155(2): 477–482.
23. Di Lorenzo G. Perdonà S. Damiano R. Faiella A. Cantiello F. Pignata S. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer. 2010 Apr 15; 116(8): 1893–900.
24. Divrik R.T. Yildirim Ü. Zorlu F. (2006) The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumours of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 175: 1641–1644.
25. Draga R.O. Grimbergen M.C. Kok E.T. Jonges T.N. van Swol C.F. Bosch J.L. Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy. Eur Urol. 2010 Apr; 57(4): 655–60. Epub 2009 Oct 6.
26. Draga R.O. Grimbergen M.C. Vijverberg P.L. van Swol C.F. Jonges T.G. Kummer J.A. Ruud Bosch J.L. (2010b) In vivo bladder cancer diagnosis by high-volume Raman spectroscopy. Anal Chem 82: 5993–5999.
27. Duchek M. Johansson R. Jahnson S. Mestad O. Hellström P. Hellsten S. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol. 2010 Jan; 57(1): 25–31. Epub 2009 Oct 6.
28. Epstein J.I. Amin M.B. Reuter V.R. Mostofi F.K. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998 Dec; 22(12): 1435–48.
29. Feld M.S. Manoharan R. Salenius J. (1995) Detection and characterization of human tissue lesions with near infra-red Raman spectroscopy. Adv Fluorescence Sensing Technol II(SPIE 2388): 99–102.
30. Fernandez-Gomez J. Madero R. Solsona E. (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guérin: the CUETO scoring model. J Urol 2009 182: 2195–2203 “http://www.ncbi.nlm.nih.gov/pubmed?term=%22Fleshner%20N%22%5BAuthor%5D” Fleshner N, HYPERLINK “http://www.ncbi.nlm.nih.gov/pubmed?term=%22Garland%20J%22%5BAuthor%5D” Garland J, HYPERLINK “http://www.ncbi.nlm.nih.gov/pubmed?term=%22Moadel%20A%22%5BAuthor%5D” Moadel A, HYPERLINK “http://www.ncbi.nlm.nih.gov/pubmed?term=%22Herr%20H%22%5BAuthor%5D” Herr H, HYPERLINK “http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ostroff%20J%22%5BAuthor%5D” Ostroff J, HYPERLINK “http://www.ncbi.nlm.nih.gov/pubmed?term=%22Trambert%20R%22%5BAuthor%5D” Trambert R, HYPERLINK “http://www.ncbi.nlm.nih.gov/pubmed?term=%22O–Sullivan%20M%22%5BAuthor%5D” O–Sullivan M, HYPERLINK “http://www.ncbi.nlm.nih.gov/pubmed?term=%22Russo%20P%22%5BAuthor%5D” Russo P. HYPERLINK “http://www.ncbi.nlm.nih.gov/pubmed/10590376” \l “#” \o “Cancer.” Cancer Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer.1999 Dec 1; 86(11): 2337–45.
31. Fujii Y. Kawakami S. Koga F. Nemoto T. Kihara K. Long-term outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int 2003 Oct; 92(6): 559–562.
32. Gallagher B.L. Joudi F.N. Maymí J.L. O–Donnell M.A. (2008) Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. Urology 71: 297–301.
33. Ghoneim M.A. Abdel-Latif M. el-Mekresh M. Abol-Enein H. Mosbah A. Ashamallah A. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol. 2008 Jul; 180(1): 121–7. Epub 2008 May 15.
34. Gofrit O.N. Pode D. Lazar A. Katz R. Shapiro A. Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol. 2006 Feb; 49(2): 303–6; discussion 306–307. Epub 2006 Jan 6.
35. Goh A.C. Tresser N.J. Shen S.S. Lerner S.P. (2008) Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology 72: 133–137.
36. Gohji K. Nomi M. Okamoto M. Takenaka A. Hara I. Okada H. Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder. Urology. 1999 Feb; 53(2): 308–13.
37. Gontero P. Frea B. Actual experience and future development of gemcitabine in superficial bladder cancer. Ann Oncol. 2006 May; 17 Suppl 5: v123–128. Review.
38. Griffiths T.R. Charlton M. Neal D.E. Powell P.H. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol. 2002 Jun; 167(6): 2408–12.
39. Grimm M.O. Steinhoff C. Simon X. Spiegelhalder P. Ackermann R. Vogeli T.A. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol. 2003 Aug; 170(2 Pt 1): 433–7.
40. Han R.F. Pan J.G. (2006) Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 67: 1216–1223.
41. Hautmann R.E. Gschwend J.E. de Petriconi R.C. Kron M. Volkmer B.G. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol. 2006 Aug; 176(2): 486–92; discussion 491–2.
42. Hendricksen K. van der Heijden A.G. Cornel E.B. Vergunst H. de Reijke T.M. van Boven E. Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol. 2009 Jun; 27(3): 337–42. Epub 2009 Feb 13.
43. Heney N.M. Nocks B.N. Daly J.J. Prout G.R. Jr Newall J.B. Griffin P.P. Perrone T.L. Szyfelbein W.A. Ta and T1 bladder cancer: location, recurrence and progression. Br J Urol. 1982 Apr; 54(2): 152–157.
44. Hinotsu S. Akaza H. Ohashi Y. Kotake T. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer. 1999 Nov 1; 86(9): 1818–26.
45. Holmäng S. Follow-up of patients with noninvasive and superficially invasive bladder cancer. Semin Urol Oncol. 2000 Nov; 18(4): 273–279.
46. Holzbeierlein J.M. Smith J.A. Jr. Surgical management of noninvasive bladder cancer (stages Ta/T1/CIS). Urol Clin North Am. 2000 Feb; 27(1): 15–24, vii-viii. Review.
47. Hong Y.M. Loughlin K.R. (2008) Economic impact of tumor markers in bladder cancer surveillance. Urology 71: 131–135.
48. Hudson M.A. Herr H.W. (1995) Carcinoma in situ of the bladder. J Urol 153: 564–572.
49. Hungerhuber E. Stepp H. Kriegmair M. Stief C. Hofstetter A. Hartmann A. Seven years– experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology. 2007 Feb; 69(2): 260–4.
50. Hurle R. Losa A. Manzetti A. Lembo A. (1999) Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 54: 258–263.
51. Jain A. Phillips R.M. Scally A.J. Lenaz G. Beer M. Puri R. (2009) Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. Urology 73: 1083–1086.
52. Järvinen R. Kaasinen E. Sankila A. Rintala E. FinnBladder Group. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol. 2009 Aug; 56(2): 260–5. Epub 2009 Apr 16.
53. Jemal A. Murray T. Ward E. Samuels A. Tiwari R.C. Ghafoor A. Feuer E.J. Thun M.J. Cancer statistics, 2005. CA Cancer J Clin. 2005 Jan-Feb; 55(1): 10–30.
54. Jichlinski P. Guillou L. Karlsen S.J. Malmström P.U. Jocham D. Brennhovd B. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer–a multicenter study. J Urol. 2003 Jul; 170(1): 226–9.
55. Jimenez-Cruz J.F. Vera-Donoso C.D. Leiva O. Pamplona M. Rioja-Sanz L.A. Martinez-Lasierra M. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha. Urology. 1997 Oct; 50(4): 529–35.
56. Koshikawa T. Leyh H. Schenck U. (1989) Difficulties in evaluating urinary specimens after local mitomycin therapy of bladder cancer. Diagn Cytopathol 5: 117–121.
57. Kulkarni G.S. Hakenberg O.W. Gschwend J.E. Thalmann G. Kassouf W. Kamat A. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol. 2010 Jan; 57(1): 60–70. Epub 2009 Sep 1.
58. Kurth K.H. Schellhammer P.F. Okajima E. (1995) Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Int J Urol 2(Suppl. 2): 8–22.
59. Lamm D.L. van der Meijden P.M. Morales A. Brosman S.A. Catalona W.J. Herr H.W. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992 Mar; 147(3): 596–600.
60. Leblanc B. Duclos A.J. Bénard F. Côté J. Valiquette L. Paquin J.M. Long-term followup of initial Ta grade 1 transitional cell carcinoma of the bladder. J Urol. 1999 Dec; 162(6): 1946–1950.
61. Lerner S.P. Tangen C.M. Sucharew H. Wood D. Crawford E.D. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol. 2009 Mar-Apr; 27(2): 155–9. Epub 2008 Mar 4.
62. Levi A.W. Potter S.R. Schoenberg M.P. Epstein J.I. Clinical significance of denuded urothelium in bladder biopsy. J Urol. 2001 Aug; 166(2): 457–60.
63. Lightfoot A.J. Rosevear H.M. O–Donnell M.A. Recognition and treatment of BCG failure in bladder cancer. Scientific World Journal. 2011 Mar 7; 11: 602–613.
64. Lokeshwar V.B. Habuchi T. Grossman H.B. Murphy W.M. Hautmann SH Hemstreet G.P. 3rd, Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2005 Dec; 66(6 Suppl 1): 35–63.
65. Lopez-Beltran A. Bassi P. Pavone-Macaluso M. Montironi R. (2004) Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur Urol 45: 257–266.
66. Losa A. Hurle R. Lembo A. (2000) Low dose bacillus Calmette-Guérin for carcinoma in situ of the bladder: long-term results. J Urol 163: 68–72.
67. Madersbacher S. Hochreiter W. Burkhard F. Thalmann G.N. Danuser H. Markwalder R. Radical cystectomy for bladder cancer today–a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003 Feb 15; 21(4): 690–6.
68. Malmström P.U. Sylvester R.J. Crawford D.E. Friedrich M. Krege S. Rintala E. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009 Aug; 56(2): 247–56. Epub 2009 Apr 24.
69. Martínez-Piñeiro J.A. Flores N. Isorna S. Solsona E. Sebastián J.L. Pertusa C., for CUETO (Club Urológico Español de Tratamiento Oncológico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int. 2002 May; 89(7): 671–680.
70. Matzkin H. Soloway M.S. Hardeman S. Transitional cell carcinoma of the prostate. J Urol. 1991 Nov; 146(5): 1207–1212.
71. May M. Brookman-Amissah S. Roigas J. Hartmann A. Störkel S. Kristiansen G. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol. 2010 May; 57(5): 850–8. Epub 2009 Mar 31.
72. McCahy P.J. Harris C.A. Neal E. (1997) The accuracy of recording of occupational history in patients with bladder cancer. Br J Urol 79: 91–93.
73. Miki M. Shiozawa H. Matsumoto T. Aizawa T. Transurethral resection in saline (TURis): a newly developed TUR system preventing obturator nerve reflex Nihon Hinyokika Gakkai Zasshi. 2003 Nov; 94(7): 671–7.
74. Miladi M. Peyromaure M. Zerbib M. Saïghi D. Debré B. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol. 2003 Mar; 43(3): 241–5.
75. Millán-Rodríguez F. Chéchile-Toniolo G. Salvador-Bayarri J. Huguet-Pérez J. Vicente-Rodríguez J. Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. J Urol. 2000 Oct; 164(4): 1183–7.
76. Millán-Rodríguez F. Chéchile-Toniolo G. Salvador-Bayarri J. Palou J. Algaba F. Vicente-Rodríguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 2000 Sep; 164(3 Pt 1): 680–4.
77. Mohanty N.K. Nayak R.L. Vasudeva P. Arora R.P. (2008) Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience. Urol Oncol 26: 616–619.
78. Morales A. Eidinger D. Bruce A.W. (1976) Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116: 180–183.
79. Mungan M.U. Canda A.E. Tuzel E. Yorukoglu K. Kirkali Z. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. Eur Urol. 2005 Nov; 48(5): 760–3. Epub 2005 Jul 1.
80. Nadler R.B. Catalona W.J. Hudson M.A. Ratliff T.L. Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol. 1994 Aug; 152(2 Pt 1): 367–373.
81. Nativ O. Witjes J.A. Hendricksen K. (2009) Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guérin. J Urol 182: 1313–1317.
82. Nguyen C.T. Jones J.S. (2008) Defining the role of NMP22 in bladder cancer surveillance. World J Urol 26: 51–58.
83. Oge O. Erdem E. Atsü N. Ahin A. Ozen H. Proposal for changes in cystoscopic follow-up of patients with low-grade pTa bladder tumor. Eur Urol. 2000 Mar; 37(3): 271–274.
84. Otto W. Denzinger S. Fritsche H.M. Burger M. Wieland W.F Hofstädter F. (2010) The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int 107: 404–408.
85. Pan C.C. Chang Y.H. Chen K.K. Yu H.J. Sun C.H. Ho D.M. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am J Clin Pathol. 2010 May; 133(5): 788–95.
86. Pansadoro V. Emiliozzi P. Defidio L. Donadio D. Florio A. Maurelli S. Bacillus Calmette-Guérin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results. J Urol 154: 2054–2058.
87. Pawinski A. Sylvester R. Kurth K.H. Bouffioux C. van der Meijden A. Parmar M.K. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol. 1996 Dec; 156(6): 1934–40, discussion 1940–1.
88. Ploeg M. Aben K.K.H. Kiemeney L.A. (2009) The present and future burden of urinary bladder cancer in the world. World J Urol 27: 289–293.
89. Puente D. Harge P. Greiser E. (2006) A pooled analysis of bladder cancer case–control studies evaluating smoking in men and women. Cancer Causes Contr 17: 71–79.
90. Raitanen M.P. Aine R. Rintala E. Kallio J. Rajala P. Juusela H. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol. 2002 Mar; 41(3): 284–9.
91. Raj G.V. Herr H. Serio A.M. (2007) Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177: 1283–1286.
92. Raj G.V. Herr H. Serio A.M. Donat S.M. Bochner B.H. Vickers A.J. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol. 2007 Apr; 177(4): 1283–6; discussion 1286.
93. Ratliff T.L. Ritchey J.K. Brandhorst J. Hanna M.G. Jr (1994) Time-dependent aggregation of reconstituted BCG vaccine. J Urol 152: 2147–2150.
94. Rodríguez F. Palou J. Martínez R. Rodríguez O. Rosales A. Huguet J. Villavicencio H. Practical guideline for the management of adverse events associated with BCG installations. Arch Esp Urol. 2008 Jun; 61(5): 591–6.
95. Samanic C.M. Kogevinas M. Silverman D.T. Tardón A. Serra C. Malats N. Occupation and bladder cancer in a hospital-based case-control study in Spain. Occup Environ Med. 2008 May; 65(5): 347–53. Epub 2007 Oct 19.
96. Sauter G. Algaba F. Amin M. (2004) Tumours of the urinary system: non-invasive urothelial neoplasias. In: Eble J.N. Sauter G. Epstein J.l. Sesterhenn I. (eds) WHO classification of Tumours of the Urinary System and Male Genital Organs. Lyon: IARCC Press, pp. 29–34.
97. Schips L. Augustin H. Zigeuner R.E. (2002) Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 59: 220–223.
98. Schlomer B.J. Ho R. Sagalowsky A. (2010) Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 183: 62–67.
99. Schmidbauer J. Witjes F. Schmeller N. Donat R. Susani M. Marberger M. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol. 2004 Jan; 171(1): 135–8.
100. Schmitz-Drager B.J. Beiche B. Tirsar L.A. (2007) Immunocytology in the assessment of patients with asymptomatic microhaematuria. Eur Urol 51: 1582–1588.
101. Schumacher M.C. Holmäng S. Davidsson T. Friedrich B. Pedersen J. Wiklund N.P. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol. 2010 Feb; 57(2): 293–9. Epub 2009 Nov 6.
102. Schwaibold H.E. Sivalingam S. May F. Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int. 2006 Jun; 97(6): 1199–1201.
103. Shariat S.F. Karakiewicz P.I. Palapattu G.S. Lotan Y. Rogers C.G. Amiel G.E. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006 Dec; 176(6 Pt 1): 2414–22; discussion 2422.
104. Shariat S.F. Karam J.A. Lerner S.P. (2008) Molecular markers in bladder cancer. Curr Opin Urol 18: 1–8.
105. Shariat S.F. Palapattu G.S. Amiel G.E. Karakiewicz P.I. Rogers C.G. Vazina A. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. Urology. 2006 Sep; 68(3): 538–42. Epub 2006 Sep 18.
106. Shelley M.D. Kynaston H. Court J. Wilt T.J. Coles B. Burgon K. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001 Aug; 88(3): 209–16.
107. Shelley M.D. Wilt T.J. Court J. (2004) Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a metaanalysis of randomized trials. BJU Int 93: 485–490.
108. Shiozawa H. Aizawa T. Ito T. Miki M. A new transurethral resection system: operating in saline environment precludes obturator nerve reflexes. J Urol. 2002 Dec; 168(6): 2665–7
109. Smith J.A. Jr Labasky R.F. Cockett A.T. Fracchia J.A. Montie J.E. Rowland R.G. Bladder cancer clinical guidelines panel summary report on the management of non-muscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol. 1999 Nov; 162(5): 1697–1701.
110. Sobin L.H. Gospodariwicz M. Wittekind C. (eds) (2009) TNM Classification of Malignant Tumors. UICC International Union Against Cancer. 7th edn. Oxford: Wiley-Blackwell, pp. 262–265.
111. Soloway M.S. It is time to abandon the “superficial” in bladder cancer. Eur Urol. 2007 Dec; 52(6): 1564–5. Epub 2007 Jul 17.
112. Soloway M. Bruck D.S. Kim S.S. (2003) Expectant management of small recurrent, non-invasive papillary bladder tumours. J Urol 170: 438–441.
113. Solsona E. Iborra I. Dumont R. Rubio-Briones J. Casanova J. Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol. 2000 Sep; 164(3 Pt 1): 685–9.
114. Solsona E. Iborra I. Ricos J.V. (1996) Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications. J Urol 155: 895–899.
115. Solsona E. Iborra I. Ricós J.V. Monrós J.L. Casanova J. Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol. 1999 Apr; 161(4): 1120–3.
116. Solsona E. Iborra I. Ricós J.V. Monrós J.L. Dumont R. Almenar S. Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications. J Urol. 1996 Mar; 155(3): 895–9; discussion 899–900.
117. Stein J.P. Lieskovsky G. Cote R. Groshen S. Feng A.C. Boyd S. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001 Feb 1; 19(3): 666–75.
118. Stenzl A. Burger M. Fradet Y. Mynderse L.A. Soloway M.S. Witjes J.A. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol. 2010 Nov; 184(5): 1907–13. Epub 2010 Sep 17.
119. Sylvester R.J. Brausi M.A. Kirkels W.J. Hoeltl W. Calais Da Silva F. Powell P.H. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010 May; 57(5): 766–73. Epub 2009 Dec 18.
120. Sylvester R.J. van der Meijden A. Witjes J.A. Jakse G. Nonomura N. Cheng C. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology. 2005 Dec; 66(6 Suppl 1): 90–107.
121. Sylvester R.J. van der Meijden A.P. Witjes J.A. Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005 Jul; 174(1): 86–91; discussion 91–2.
122. Sylvester R.J. van der Meijden A.P. Oosterlinck W. Witjes J.A. Bouffioux C. Denis L. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar; 49(3): 466–5; discussion 475–7. Epub 2006 Jan 17.
123. Tilki D. Burger M. Dalbagni G. Grossman H.B. Hakenberg O.W. Palou J. (2011) Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol 60: 484–592.
124. van der, Heijden A.G. Moonen P.M. Cornel E.B. Vergunst H. de Reijke T.M. van Boven E. (2006) Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol 176: 1349–1353.
125. van der Meijden A. Oosterlinck W. Brausi M. Kurth K.H. Sylvester R. de Balincourt C. Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur Urol. 1999 Apr; 35(4): 267–71.
126. Van der Meijden A. Sylvester R. Collette L. (2000) The role and impact of pathology review on stage and grade assessment on stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. J Urol 164: 1533–1537.
127. van der Meijden A.P. Sylvester R. Oosterlinck W. Solsona E. Boehle A. Lobel B. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol. 2005 Sep; 48(3): 363–71.
128. van der Meijden A.P. Sylvester R.J. Oosterlinck W. Hoeltl W. Bono A.V. EORTC Genito-Urinary Tract Cancer Group. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 2003 Oct; 44(4): 429–34.
129. van Gils-Gielen R.J. Witjes W.P. Caris C.T. Debruyne F.M. Witjes J.A. Oosterhof G.O. Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Urology. 1995 Apr; 45(4): 581–6.
130. Van Rhijn B.W.G. van der Kwast T.H. Kakiashvili D.M. (2010a) Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int 106: 206–211.
131. Varkarakis M.J. Gaeta J. Moore R.H. Murphy G.P. Superficial bladder tumor. Aspects of clinical progression. Urology. 1974 Oct; 4(4): 414–420.
132. Witjes A. Hendricksen K. Gofrit O. Risi O. Nativ O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol. 2009 Jun; 27(3): 319–324. Epub 2009 Feb 22.
133. Witjes J.A. Redorta J.P. Jacqmin D. Sofras F. Malmström P.U. Riedl C. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol. 2010 Apr; 57(4): 607–14. Epub 2010 Jan 22.
134. Yates D.R. Roupret M. (2010) Failure of bacille Calmette-Guérin in patients with high risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options. BJU Int 106: 162–167.
135. Zeegers M.P. Swaen G.M. Kant I. Goldbohm R.A. van den Brandt P.A. Occupational risk factors for male bladder cancer: results from a population based case cohort study in the Netherlands. Occup Environ Med. 2001 Sep; 58(9): 590–6.
136. Zeegers M.P. Tan F.E. Dorant E. van Den Brandt P.A. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer. 2000 Aug 1; 89(3): 630–9.
137. Zlotta A.R. van Vooren J.P. Huygen K. Drowart A. Decock M. Pirson M. Jurion F. Palfliet K. Denis O. Simon J. Schulman C.C. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol. 2000 Apr; 37(4): 470–77.
138. Zlotta A.R. Fleshner N.E. Jewett M.A. (2009) The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J 3(6 Suppl. 4): S199–S205.